Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2012-03-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ibuprofen
Ibuprofen
10 mg/kg every 8 hours until 24 hours after resolution of fever
acetaminophen
Acetaminophen
15 mg/kg every 6 hours until 24 hours after resolution of fever
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibuprofen
10 mg/kg every 8 hours until 24 hours after resolution of fever
Acetaminophen
15 mg/kg every 6 hours until 24 hours after resolution of fever
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* admission in Schneider childrenMC of Israel, wards a/c
* clinical diagnosis of pneumonia with evidence of pleural effusion on chest X-ray
* parental informed consent
* follow-up ability after discharge
Exclusion Criteria
* immune deficiency
* chronic lung disease other than asthma (CF, CLD of prematurity, Familial Dysautonomia, etc)
* significant premorbidity (organ failure, rheumatic disease, etc)
* endotracheal/endobronchial devices including tracheostomy.
* parental refusal to participate in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
havatzelet yarden-bilavsky, MD
Role: PRINCIPAL_INVESTIGATOR
schneider children MC of Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Schneider's medical center of Israel
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
262-11-RMC
Identifier Type: -
Identifier Source: org_study_id